CEX.IO’s Mark Taylor, Global Head of Financial Crime to Join Panel Organized by C5
23 avr. 2024 08h00 HE
|
CEX.IO
CHICAGO, April 23, 2024 (GLOBE NEWSWIRE) -- CEX.IO, a global ecosystem of products and services that connects curious participants to the cryptocurrency economy and decentralized finance (DeFi),...
Global C5 Complement Inhibitors Drug Market Opportunity USD 15 Billion 2026
17 avr. 2021 14h43 HE
|
KuicK Research
DELHI, India, April 17, 2021 (GLOBE NEWSWIRE) -- “Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026” Report Highlights: Global C5...
Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets
24 avr. 2017 07h15 HE
|
Akari Therapeutics, Plc
-Interim Phase 2 PNH data demonstrate positive response with Coversin™-Phase 3 PNH program expected to commence in 4Q2017-Data from preclinical aHUS model demonstrates positive results-New preclinical...
Akari Therapeutics to Present at the Jefferies Complement Symposium
03 avr. 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, April 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Akari Therapeutics Announces FDA Fast Track Designation For Coversin
30 mars 2017 16h02 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, March 30, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the US Food and Drug...
Akari Therapeutics Announces R&D Day on April 24, 2017
17 mars 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, March 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research...
Akari Therapeutics to Present at the 29th Annual ROTH Conference
07 mars 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, March 07, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Akari Therapeutics to Attend Upcoming Investor Conferences in February
31 janv. 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that senior management will...
Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans
04 janv. 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, has expanded its clinical and regulatory teams....
Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH
03 janv. 2017 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug...